Video
Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence
Author(s):
Video Player is loading.
In this video, David A. Ginsberg, MD, discusses the takeaways of the study, “Long-term, repeat treatments with onabotulinumtoxinA are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.
Related Videos
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Related Content
